Evolving NSCLC Treatment Paradigm

Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.